DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Inclusion Criteria: * PRE-REGISTRATION INCLUSION CRITERIA * Presence of active, chronic HCV infection confirmed by positive HCV RNA * Willingness to use adequate contraception to avoid pregnancy or impregnation for the duration of study participation; Note: * The effects of INO-8000 with or without INO-9012 on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation * For men and women who are not postmenopausal (i.e., \>= 12 months of non-therapy-induced amenorrhea, confirmed by follicle stimulating hormone \[FSH\], if not on hormone replacement) or surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females), agreement to remain abstinent or use highly effective or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and at least through week 12 after last dose * Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception * Examples of contraceptive methods with an expected failure rate of \< 1% per year include male sterilization and hormonal implants; alternat…